Mahsima Shabani

Mahsima Shabani

Auto-generated profile, based on publicly available information

Mahsima Shabani

Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2021 in Radiology
Verified
Journal Article
Closed access
FPFarhad Pishgar
Farhad Pishgar
MSMahsima Shabani
Mahsima Shabani
TSThiago Quinaglia A. C. Silva
Thiago Quinaglia A. C. Silva
DBDavid A. Bluemke
David A. Bluemke
MBMatthew Budoff
Matthew Budoff
SDShadpour Demehri
Shadpour Demehri
Assessment of soft-tissue composition in participants with chronic obstructive pulmonary disease extended the predictive value of chest CT examinations beyond their primary clinical indications for... Background Obesity and sarcopenia are associated with mortality in chronic obstructive pulmonary disease (COPD). Routine chest CT examinations may allow assessment of obesity and sarcopenia by soft...

1 August 2021 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
JLJacqueline Latina
Jacqueline Latina
MSMahsima Shabani
Mahsima Shabani
KKKaran Kapoor
Karan Kapoor
SWSeamus P. Whelton
Seamus P. Whelton
JTJeffrey C. Trost
Jeffrey C. Trost
AAArmin Arbab-Zadeh
Armin Arbab-Zadeh
This study's initial experience with coronary angiography using ultrahigh-resolution CT in patients suspected of having coronary stenoses demonstrates promise for high diagnostic accuracy even in t... Purpose Conventional CT technology yields only modest accuracy of coronary artery stenosis assessment in severely calcified lesions. Reported herein are this study's initial observations on the pot...

25 October 2022 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
MSMosayeb Soleymani
Mosayeb Soleymani
FMFarzad Masoudkabir
Farzad Masoudkabir
MSMahsima Shabani
Mahsima Shabani
AVAli Vasheghani-Farahani
Ali Vasheghani-Farahani
ABAmir Hossein Behnoush
Amir Hossein Behnoush
AKAmirmohammad Khalaji
Amirmohammad Khalaji
Microvascular angina (MVA), historically called cardiac syndrome X, refers to angina with nonobstructive coronary artery disease. This female-predominant cardiovascular disorder adds considerable health-related costs due to repeated diagnostic angiography and frequent hospital admissions. Despite the high prevalence of this diagnosis in patients undergoing coronary angiography, it is still a therapeutic challenge for cardiologists. Unlike obstructive coronary artery disease, with multiple evidence-based therapies and management guidelines, little is known regarding the management of MVA. During the last decade, many therapeutic interventions have been suggested for the treatment of MVA. However, there is a lack of summarization tab and update of current knowledge about pharmacologic management of MVA, mostly due to unclear pathophysiology. In this article, we have reviewed the underlying mechanisms of MVA and the outcomes of various medications in patients with this disease. Contrary to vasospastic angina in which normal angiogram is observed as well, nitrates are not effective in the treatment of MVA. Beta-blockers and calcium channel blockers have the strongest evidence of improving the symptoms. Moreover, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, estrogen, and novel antianginal drugs has had promising outcomes. Investigations are still ongoing for vitamin D, omega-3, incretins, and n-acetyl cysteine, which have resulted in beneficial initial outcomes. We believe that the employment of the available results and results of the future large-scale trials into cardiac care guidelines would help reduce the global cost of cardiac care tremendously.

24 October 2022 in Clinical Genetics
Verified
Journal Article
Closed access
MSMahsima Shabani
Mahsima Shabani
AAAshkan Abdollahi
Ashkan Abdollahi
BBBobby K. Brar
Bobby K. Brar
GMGretchen L. MacCarrick
Gretchen L. MacCarrick
BVBharath Ambale Venkatesh
Bharath Ambale Venkatesh
JBJoann N. Bodurtha
Joann N. Bodurtha

10 May 2023 in JACC: Advances
Verified
Journal Article
Open access
OCOmar Chehab
Omar Chehab
MSMahsima Shabani
Mahsima Shabani
VVVinithra Varadarajan
Vinithra Varadarajan
CWCollin O. Wu
Collin O. Wu
KWKarol E. Watson
Karol E. Watson
JLJoao A. C. Lima
Joao A. C. Lima
Sex hormone (SH) imbalances have been linked to a higher risk of heart failure in both sexes. However, mechanisms that underlie this relationship remain unclear. We examined the association of baseline SH with interstitial and replacement myocardial fibrosis in the MESA (Multi-Ethnic Study of Atherosclerosis) using cardiac magnetic resonance (CMR) T1 mapping and late gadolinium enhancement (LGE). The purpose of this study was to assess the link between baseline sex hormone levels and myocardial fibrosis in the MESA cohort using CMR. A total of 2,324 participants (men and postmenopausal women [PMW]) were included in the MESA with SH measured at baseline and had underwent CMR 10 years later. All analyses were stratified by sex and age. Regression models were constructed to assess the associations of baseline SH with extracellular volume (ECV)% and native T1 time and with LGE. Higher native T1 time and ECV% are interpreted as evidence of increasing interstitial myocardial fibrosis (IMF). Given the limited number of myocardial scars present in PMW, analysis of LGE was limited to men. Among older men (age ≥65 years), a 1-SD increment higher free testosterone was significantly associated with 2.45% lower ECV% and 21.5% lower native T1 time, while a 1-SD increment higher bioavailable testosterone was associated with 12.5% lower native T1 time. A 1-SD increment greater sex hormone-binding globulin level was associated with 1% higher ECV%. Among PMW of 55 to 64 years, a 1-SD increment higher total testosterone was associated with 9.5% lower native T1 time. Higher levels of estradiol in older men were independently associated with higher odds of having a myocardial scar (OR: 4.10; 95% CI: 1.35–12.40; P = 0.01). Among older men, SH imbalances at initial evaluation were independently associated with CMR defined IMF and replacement fibrosis, respectively; while increasing total testosterone in middle-aged PMW was associated with lesser marker of IMF. (JACC Adv 2023;2:100320) Published by Elsevier on behalf of the American College of Cardiology Foundation.

9 July 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
FPFarhad Pishgar
Farhad Pishgar
MSMahsima Shabani
Mahsima Shabani
TSThiago Quinaglia A. C. Silva
Thiago Quinaglia A. C. Silva
DBDavid A. Bluemke
David A. Bluemke
Matthew Jay BudoffMatthew Jay Budoff
Matthew Jay Budoff
SDShadpour Demehri
Shadpour Demehri
Background: Given the central role of skeletal muscles in glucose homeostasis, deposition of adipose depots beneath the fascia of muscles (versus subcutaneous adipose tissue [SAT]) may precede insulin resistance and type 2 diabetes (T2D) incidence. This study was aimed to investigate the associations between computed tomography (CT)–derived biomarkers for adipose tissue and T2D incidence in normoglycemic adults.Methods and findings: This study was a population-based multiethnic retrospective cohort of 1,744 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) with normoglycemia (baseline fasting plasma glucose [FPG] less than 100 mg/dL) from 6 United States of America communities. Participants were followed from April 2010 and January 2012 to December 2017, for a median of 7 years. The intermuscular adipose tissue (IMAT) and SAT areas were measured in baseline chest CT exams and were corrected by height squared (SAT and IMAT indices) using a predefined measurement protocol. T2D incidence, as the main outcome, was based on follow-up FPG, review of hospital records, or self-reported physician diagnoses.Participants’ mean age was 69 ± 9 years at baseline, and 977 (56.0%) were women. Over a median of 7 years, 103 (5.9%) participants were diagnosed with T2D, and 147 (8.4%) participants died. The IMAT index (hazard ratio [HR]: 1.27 [95% confidence interval [CI]: 1.15–1.41] per 1-standard deviation [SD] increment) and the SAT index (HR: 1.43 [95% CI: 1.16–1.77] per 1-SD increment) at baseline were associated with T2D incidence over the follow-up. The associations of the IMAT and SAT indices with T2D incidence were attenuated after adjustment for body mass index (BMI) and waist circumference, with HRs of 1.23 (95% CI: 1.09–1.38) and 1.29 (95% CI: 0.96–1.74) per 1-SD increment, respectively. The limitations of this study include unmeasured residual confounders and one-time measurement of adipose tissue biomarkers.Conclusions: In this study, we observed an association between IMAT at baseline and T2D incidence over the follow-up. This study suggests the potential role of intermuscular adipose depots in the pathophysiology of T2D.Trial registration: ClinicalTrials.govNCT00005487